Accueil・Liste d'Actions・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Fermé

SecteurSoins de santé

72.44 -4.65

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

73.28

Max

76.69

Chiffres clés
By Trading Economics
Revenu	11M -156M
Ventes	28M 222M
BPA	-0.78
Marge bénéficiaire	-70.082
Employés	999
EBITDA	-24M -137M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+46.39% upside

Dividendes
By Acuity
Prochains Résultats	28 oct. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-2B 15B
Ouverture précédente	77.09
Clôture précédente	72.44

Sentiment de l'Actualité

By Acuity

24%

76%

51 / 339 Classement par Healthcare

Bridgebio Pharma Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 sept. 2026, 22:46 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, despite no specific news. Broader market pressure persists from rising crude oil prices above $100.

2 sept. 2026, 19:36 UTC

Social Media

News

Event

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

1 sept. 2026, 23:16 UTC

News

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

28 août 2026, 20:08 UTC

Social Media

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

20 août 2026, 19:46 UTC

Correlated Moves

Shares lower amid broader biotechnology sector decline.

19 août 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18 août 2026, 20:06 UTC

Social Media

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14 août 2026, 20:06 UTC

Social Media

News

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13 août 2026, 23:01 UTC

News

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12 août 2026, 19:51 UTC

News

Social Media

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11 août 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10 août 2026, 23:21 UTC

News

Social Media

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7 août 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 août 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 août 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 août 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 août 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 juil. 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 juil. 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 juil. 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 juil. 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 juil. 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Comparaison

Variation de prix

Bridgebio Pharma Inc prévision

Objectif de Prix

By TipRanks

46.39% hausse

Prévisions sur 12 Mois

Moyen 109.44 USD 46.39%

Haut 157 USD

Bas 94 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

Achat

Maintien

Vente

Basé sur 17 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

51 / 339Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.